Home » Stocks » PIRS

Pieris Pharmaceuticals, Inc. (PIRS)

Stock Price: $1.81 USD -0.12 (-6.22%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 114.58M
Revenue (ttm) 29.32M
Net Income (ttm) -37.23M
Shares Out 54.48M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $1.81
Previous Close $1.93
Change ($) -0.12
Change (%) -6.22%
Day's Open 1.90
Day's Range 1.80 - 1.93
Day's Volume 535,258
52-Week Range 1.70 - 3.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...

23 hours ago - Accesswire

Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the program,...

2 weeks ago - Accesswire

Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in he...

1 month ago - Accesswire

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -8.33% and -50.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 5.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% over the past year to ($0.26)...

1 month ago - Benzinga

Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZen...

1 month ago - Accesswire

On Tuesday, March 30, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

1 month ago - Benzinga

Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target coll...

1 month ago - Accesswire

BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...

1 month ago - Accesswire

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno...

3 months ago - Accesswire

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -62.50% and -67.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...

6 months ago - Zacks Investment Research

  Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.

6 months ago - Benzinga

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.

9 months ago - Benzinga

NEW YORK, July 21, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).

9 months ago - PRNewsWire

Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: MGTX, NTLA, QURE, VRTX, GNOM
1 year ago - Zacks Investment Research

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: MGTX, NTLA, QURE, VRTX
1 year ago - Zacks Investment Research

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

The stock of Pieris Pharmaceuticals has made a nice move so far in September.

1 year ago - Seeking Alpha

Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Here are four stocks that appear to be at or near a breakout point: Enphase Energy, Inc.

Other stocks mentioned: ENPH, QD, TAL
1 year ago - Benzinga

Investors need to pay close attention to Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Shares have fallen by 30% since my initial and update articles.

1 year ago - Seeking Alpha

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About PIRS

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment o... [Read more...]

Industry
Biotechnology
CEO
Stephen Yoder
Employees
111
Stock Exchange
NASDAQ
Ticker Symbol
PIRS
Full Company Profile

Financial Performance

In 2020, PIRS's revenue was $29.32 million, a decrease of -36.64% compared to the previous year's $46.28 million. Losses were -$37.23 million, 46.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for PIRS stock is "Strong Buy." The 12-month stock price forecast is 9.00, which is an increase of 397.24% from the latest price.

Price Target
$9.00
(397.24% upside)
Analyst Consensus: Strong Buy